175140-17-7Relevant academic research and scientific papers
Corticotropin releasing factor antagonists
-
, (2008/06/13)
Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes fo
CRF receptor antagonists and methods relating thereto
-
Page column 15, (2010/01/30)
Compounds are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, including stroke. The compounds of this invention have the following structures: wherein n, m, R, R1, R2, X and Ar are as defined herein, including stereoisomes and pharmaceutically acceptable salts thereof.
CORTICOTROPIN RELEASING FACTOR ANTAGONISTS
-
, (2008/06/13)
Corticotropin-releasing factor (CRF) antagonists having formulae (I), (II) or (III) wherein the dashed lines, A, B, Y, Z, G, R. sub.3, R. sub.4, R. sub.5, R 6, R 16 and R 17 are as defined in the description, and processes for preparing them. These compou
Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines
Chorvat, Robert J.,Bakthavatchalam, Rajagopal,Beck, James P.,Gilligan, Paul J.,Wilde, Richard G.,Cocuzza, Anthony J.,Hobbs, Frank W.,Cheeseman, Robert S.,Curry, Matthew,Rescinito, Joseph P.,Krenitsky, Paul,Chidester, Dennis,Yarem, Jerry A.,Klaczkiewicz, John D.,Hodge, C. Nicholas,Aldrich, Paul E.,Wasserman, Zelda R.,Fernandez, Christine H.,Zaczek, Robert,Fitzgerald, Lawrence W.,Huang, Shiew-Mei,Shen, Helen L.,Wong, Y. Nancy,Chien, Ben M.,Quon, Check Y.,Arvanitis, Argyrios
, p. 833 - 848 (2007/10/03)
The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (K(i)'s 1 has been selected for further pharmacological studies that will be reported in due course.
